Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.

Keywords

Medicine, Enalapril, Asymptomatic, Heart failure, Internal medicine

References

• Pharmacogenetics: more than skin deepHoward L. McLeod — 2001
• Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure.Mark H. Drazner, J. Eduardo Rame, Lynne W. Stevenson — 2001
• Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.Peter E. Carson, Susan Ziesche, Gary R. Johnson — 1999
• Linkage disequilibrium in the human genomeDavid Reich, Michele Cargill, Stacey Bolk — 2001
• Racial differences in the outcome of left ventricular dysfunction.Daniel L. Dries, Derek V. Exner, Bernard J. Gersh — 1999
• Localization of a small genomic region associated with elevated ACE.Xiaofeng Zhu, Colin A. McKenzie, Terrence Forrester — 2000
• Heart failure in African Americans: A cardiovascular enigmaClyde W. Yancy — 2000
• Commentary: considerations for use of racial/ethnic classification in etiologic research.Jay S. Kaufman — 2001
• Racial profiling in medical research.Robert S. Schwartz — 2001
• Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.Daniel L. Dries, Nancy K. Sweitzer, Mark H. Drazner — 2001
• Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.Lawrence Y. Agodoa — 2001
• The Structure of Haplotype Blocks in the Human GenomeStacey Gabriel, S. F. Schaffner, Huy Nguyen — 2002
• Population genetic structure of variable drug responseJames F. Wilson, Michael E. Weale, Alice C. Smith — 2001
• Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.Derek V. Exner, Daniel L. Dries, Michaël Domanski — 2001
• Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.Clyde W. Yancy, Michael B. Fowler, Wilson S. Colucci — 2001
• Race and responsiveness to drugs for heart failure.Elizabeth Ofili, John M. Flack, G. W. Gibbons — 2001
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.The SOLVD Investigators* — 1992
• Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.The SOLVD Investigators — 1990

Cited by

• Inhibition of RAAS—When is it too much?Yozo Hida, Xiaoye Sherry Li, David H. Bailey — 2004
• The A's, G's, C's, and T's of health disparitiesIrène Sadowska Guillón — 2009
• Association of race, heart failure and chronic kidney disease.A.G. Shannon — 2006
• Race as a proxy for drug response: the dangers and challenges of ethnic drugs.René Bowser — 2004
• Studies of the Epidemiology and Prognosis of Patients with Heart Failure in LeicestershireJames D. Newton — 2009
• Heart failure therapy in special populations: the same or different?Clyde W. Yancy — 2004
• Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part ISara Paul, Robert L. Page — 2016
• Race, Medicine, and the Science Behind BiDil: How ACE-Inhibition Took the Fall for the First Ethnic DrugJay S. Kaufman, Thu T. Nguyen, Richard Cooper — 2010
• Race, ethnicity, and heart failure.Jalal K. Ghali — 2002
• Treatment of heart failure with abnormal left ventricular systolic function in the elderly.Wilbert S. Aronow — 2007
• Clinical trials update from the American Heart Association meeting: ACORN‐CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A‐HeFT, GEMINI, vitamin E meta‐analysis, ESCAPE, CARP, and SCD‐HeFT cost‐effectiveness studyRhidian J. Shelton, Periaswamy Velavan, Nikolay P. Nikitin — 2005
• The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?Donald A. Barr — 2005
• Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart FailureWilbert S. Aronow — 2006
• Therapies for preventing heart failureRichard F. Wright — 2003
• Racial Differences in Patients' Potassium Concentrations During Spironolactone Therapy for Heart FailureLarisa H. Cavallari, Lucy A. Fashingbauer, Amber L. Beitelshees — 2004
• Heart failure: who we treat versus who we study.Leslie W. Miller — 2008
• Cardiovascular risk factors in minorities.John C. LaRosa, Clinton D. Brown — 2005
• Darwinism and pharmacogenomics: from 'one treatment fits all' to 'selection of the richest'?Susanne Voelter‐Mahlknecht, Ulrich Mahlknecht — 2004
• Hypertension as a Risk Factor for Heart FailureArun Kannan, Rajesh Janardhanan — 2014
• The Roles of CaMKII in the Genesis of Cardiac HypertrophyJosep M. Colomer, Maddalena Illario, Anthony R. Means — 2007

Related papers

• Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction.Wilbert S. Aronow, Itzhak Kronzon — 1993
• Role of converting enzyme inhibitors in the treatment of heart failure.William B. Hood — 1993
• Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failureAndrew J.S. Coats, Stamatis Adamopoulos — 1994
• Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure.Karen Tu, Muhammad Mamdani, Alex Kopp — 2005
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).Karl Swedberg, John Kjekshus — 1988
• ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN MANAGEMENT OF PATIENTS WITH CHRONIC HEART FAILUREС. Н. Терещенко, Н. А. Джаиани — 2009
• Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.M AKonstam, M FRousseau, M WKronenberg — 1992
• Enalapril-metoprolol combination in the Treatment of Congestive Heart FailureSong Yue — 2003
• Systemic and Coronary Haemodynamics and Pharmacodynamics of Enalapril and Enalaprilat in Congestive Heart FailureKanu Chatterjee, Teresa De Marco — 2012